Cell Therapeutics Inc - SWOT Analysis

Datamonitor's Cell Therapeutics, Inc. *SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Cell Therapeutics (CTI) is a biopharmaceutical company which is focused on the development, acquisition and commercialization of anti-cancer drugs. CTI's product portfolio includes one commercial product, Zevalin, which is indicated for the treatment of transformed B-cell non-Hodgkin's lymphoma (NHL). The company primarily operates in the US and Europe. The company is headquartered in Seattle, Washington and employs about 250 people. The company recorded revenues of $0.12 million during the financial year (FY) ended December 2007, an increase of 58.8% over 2006. The increase was due to the sales of Zevalin, a commercial product acquired from Biogen in December 2007. The operating loss of the company was $133 million during FY2007, as compared to an operating loss of $98.6 million in 2006. The net loss was $138.1 million in FY2007, as compared to a net loss of $135.8 million in 2006.

Scope of the Report

• Provides all the crucial company information required for business and competitor intelligence needs
• Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
• Data is supplemented with details on the companys history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

• Support sales activities by understanding your customers businesses better

*Qualify prospective partners and suppliers

• Keep fully up to date on your competitors business structure, strategy and prospects
• Obtain the most up to date company information available